secwatch.observer — SEC 8-K summary
======================================

Issuer:     IONIS PHARMACEUTICALS INC (IONS)
CIK:        0000874015
Form:       8-K
Filed at:   2026-10-21T20:15:17+00:00
Accession:  0001140361-26-040388
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

FDA approves GSK/Ionis Hibsago (bepirovirsen) for chronic hepatitis B; Ionis earns 10-12% royalties
--------------------------------------------------------------------------------

- FDA approved Hibsago (bepirovirsen) for CHB in adults without cirrhosis, on NrtI therapy ≥6 months, with suppressed HBV DNA and HBsAg ≤3000 IU/ml.
- Phase 3 B-Well pooled data: 19% functional cure (233 of 1,220) vs 0 of 614 on placebo; 26% (200 of 768) in patients with HBsAg ≤1000 IU/ml.
- Approval granted under FDA priority review and Breakthrough Therapy Designation; bepirovirsen is also approved in Japan, with more global decisions expected.
- Ionis licensed bepirovirsen to GSK in 2019; already received upfront, license fee and milestone payments, and is eligible for more milestones plus 10-12% tiered royalties.
- CHB affects roughly 1.7 million people in the U.S.; label carries boxed warnings for on-treatment hepatic flares and thrombocytopenia.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/874015/000114036126040388/0001140361-26-040388-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/874015/000114036126040388/ef20084189_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-040388

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer